New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 21, 2014
16:40 EDTSCMPSucampo announces exclusive manufacturing, supply agreement for Lubiprostone
Sucampo Pharmaceuticals (SCMP) announced that its subsidiary, Sucampo AG, has signed an exclusive global manufacturing and supply agreement, or EMSA, with its manufacturing and development partner, R-Tech Ueno, for clinical and commercial supplies of AMITIZA, or lubiprostone, in most global markets. Under the new EMSA, Sucampo receives a new, lower price for certain components of or finished product of lubiprostone globally, except for the U.S. and Canada until the collaboration and license agreement with Takeda Pharmaceutical Company (TKPYY), expires in December 31, 2020, and except for Japan until the manufacturing and supply agreement for Japan expires or certain material circumstances occur. Additionally, under the EMSA Sucampo has the right to qualify a back-up supplier for lubiprostone in expanded circumstances, such as an authorized generic, additional formulations, and/or inability to supply product in certain circumstances, among others. The new EMSA supersedes the current manufacturing and supply agreements with R-Tech except in those situations noted above and is effective as of January 1.
News For SCMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
09:13 EDTSCMPSucampo expects approvals for AMITIZA in additional European markets in 1H15
Subscribe for More Information
09:08 EDTSCMPSucampo backs FY15 EPS 55c-65c, consensus 63c
Subscribe for More Information
07:21 EDTSCMPUBS to hold a conference
Subscribe for More Information
May 11, 2015
16:34 EDTSCMPSucampo enters into licensing agreement with Harbin Gloria Pharmaceuticals
Sucampo announced that it entered into an exclusive license, development, commercialization and supply agreement with Harbin Gloria Pharmaceuticals for AMITIZA in the People's Republic of China. Through this agreement, Sucampo has granted Gloria the rights to develop and commercialize AMITIZA in China, subject to regulatory approval of the product by the China Food and Drug Administration, or CFDA. Under the terms of the agreement, Sucampo will receive an upfront payment of $1.5M and a milestone payment from Gloria. The upfront payment will consist of $1M within 30 days of signing the agreement and $500,000 within 30 days of investigational new drug application approval in China. Sucampo will also be eligible for an additional milestone payment upon the occurrence of a regulatory or alternatively a commercial milestone event. Sucampo will be the exclusive supplier of AMITIZA to Gloria at an agreed-upon supply price. The term of this agreement is 13 years with renewal terms. Gloria will be responsible for all development activities and costs. In addition, Gloria will be responsible for all commercialization and regulatory activities in China.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use